Professor; Head of Medical Division, Turku university Hospital Ilkka Kantola - UTU Research Portal

Ilkka Kantola
Professor; Head of Medical Division, Turku university Hospital

- Docent,
Faculty of Medicine (University of Turku)

ilkkan@utu.fi

: https://orcid.org/0000-0002-6228-522X

CURRICULUM VITAE OF ILKKA KANTOLA041117.pdf

Hypertensio;Fabry disease; diabetes mellitus; sleep apnea

5 of 5

Estimating glomerular filtration rate in hypertensive subjevts: comparison of the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) Study equations (2012)
- Annals of Medicine
Korhonen Päivi, Kivelä Sirkka-Liisa, Aarnio Pertti, Kautiainen Hannu, Järvenpää Salme, Kantola Ilkka
Fabryn tauti (2012)
- Duodecim
Ilkka Kantola, Maila Penttinen, Pirjo Nuutila, Jorma Viikari
Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme (2010)
- European Journal of Heart Failure
Hawkins NM, Wang D, Petrie MC, Pfeffer MA, Swedberg K, Granger CB, Yusuf S, Solomon SD, Ostergren J, Michelson EL, Pocock SJ, Maggion AP, McMurray JJ, CHARM Investigators and Committees, Kantola I
Cardiovascular events during differing hypertension therapies in patients with diabetes (2010)
- Journal of the American College of Cardiology
Weber MA, Bakris GL, Jamerson K, Weir M, Kjedsen SE, Devereux RB, Velazquez EJ, Dahlöf B, Kelly RY, Hua TA, Hester A, Pitt B, ACCOMPLISH Investigators, Kantola I
Diabeetikon käsi- ja nivelmuutokset (2010)
- Lääkärilehti
Arkkila P, Viikari J, Kantola I
Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke (2010)
- Lancet Neurology
Rothwell PM, Howard SC, Dolan E, O´Brien E, Dobson JE, Dahlöf B, Poulter NR, Sever PS, ASCOT-BPLA and MRC Trial Investigators, Kantola I
Efficacy and safety of angiotensin receptor blockade are not mobified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme (2010)
- European Journal of Heart Failure
Chang SM, Cranger CB, Johansson PA, Kosolcharoen P, McMurray JJ, Michelson EL, Murray DR, Olofsson B, Pfeffer MA, Solomon SD, Swedberg K, Yusuf S, Dunlap ME, CHARM Investigators, Kantola I
Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan; rampril; or both:(ONTARGET/TRANSCEND)Trials (2010)
- Circulation
Böhm M, Baumhäkel M, Teo K, Sleight P, Probstfield J, Gao P, Mann JF, Diaz R, Dagenais GR, Jennings GL, Liu L, Jansky P, Yusuf S, ONTARGET/TRANSCEND Erectile Dysfunction Substudy Investigators, Kantola I
Evaluating enzyme replacement therapy in Fabry diease (2010)
- Archives of Internal Medicine -New Series-
Koskenvuo JW, Kantola IM
Fabry disease: a review of current management strategies (2010)
- QJM: An International Journal of Medicine
Mehta A, Beck M, Eyskens F, Feliciani C, Kantola I, Ramaswami U, Rolfs A, Rivera A, Waldek S, Germain DP
Metabolic syndrome; independent of its components; is a risk factor for stroke and death but not for coronary heart disease among hypertensive patients in the ASCOT-BPLA (2010)
- Diabetes Care
Gupta AK, Dahlof B, Sever PS, Poulter NR, ASCOT-BPLA Investigators, Kantola I
Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial (2010)
- Lancet
Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, Velazquez EJ, Staikos-Byrne L, Kelly RY, Shi V, Chiang YT, Weber MA, ACCOMPLISH Trial Investigators, Kantola I
The assessment of total cardiovascular risk in hypertensive subjects in primary care (2010)
- Annals of Medicine
Korhonen P, Vesalainen R, Aarnio P, Saaresranta T, Kautiainen H, Järvenpää S, Kantola I
The choice of home bood pressure result reporting method is essential: Results mailed to physicians did not improve hypertension control compared with ordinary office-based blood pressure treatment (2010)
- Blood Pressure
Varis J, Kantola I
The economic consequences of non-adherence to lipid-lowering therapy: results from the Anglo-Scandinavian-Cardiac Outcomes Trial (2010)
- International Journal of Clinical Practice
Lindgren P, Eriksson J, Buxton M, Kahan T, Poulter NR, Dahlöf B, Sever PS, Wedel H, Jönsson B, ASCOT Trial investigators, Kantola I
Tromboosiprofylaksi suomalaisessa sairaalahoidossa (2010)
- Lääkärilehti
Virtanen L, Harjola V-P, Ahonen J, Kantola I, Rintala H, Lumio J, Kellokumpu I, Kankaanranta H, Härkki P, Miettinen H, Lassila R
The effect of 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease (2006)
- Journal of Inherited Metabolic Disease
Kalliokoski RJ, Kantola I, Kalliokoski KK, Engblom E, Sundell J, Hannukainen JC, Janatuinen T, Raitakari OT, Knuuti J, Penttinen M, Viikari J, Nuutila P